Sweden-based drug development firm Beactica has announced the closure of a venture round of undisclosed, which includes backing from Uppsala University.
The institution was joined by trade union Unionen and private investors in the round, which was led by government-backed investor Almi Invest. Beactica, which was founded by former Uppsala academics, will use the funds to further develop its oncology discovery-stage programmes.
Per Källblad, Beactica CEO, said: “We are happy to close this financing round and thank existing as well as new investors. Our epigenetic programmes have already shown promise and this financing will enable us to power research forward. The investment is also an excellent development in our long-term relationship with Almi. Together with our other backers, they have created a robust framework for Beactica’s future growth.”
